LGND
HealthcareLigand Pharmaceuticals Incorporated · Biotechnology · $5B
What is Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals is a biopharmaceutical company built around a distinctive royalty and licensing model. Rather than commercializing drugs directly, Ligand partners with other pharmaceutical companies, earning royalties as those partners advance and sell medicines worldwide.
Ligand generates revenue primarily through royalties, milestones, and licensing fees tied to medicines developed by its partners. Its proprietary Captisol technology — a drug-formulation platform — is licensed broadly across the industry. The company also holds royalty interests in approved medicines spanning oncology, infectious disease, osteoporosis, and cardiovascular conditions. This asset-light structure means Ligand benefits from partner sales without bearing the full cost of clinical development or commercial operations.
Founded in 1992 and headquartered in Jupiter, Florida, Ligand has spent decades building a diversified portfolio of royalty-generating assets.
- Captisol drug-formulation technology licensed to pharmaceutical partners
- Royalty interests in oncology medicines including Kyprolis and Evomela
- Royalty stake in Veklury, used for moderate-to-severe COVID-19 treatment
- Rylaze, targeting acute lymphoblastic leukemia in adults and children
- Broad pipeline of partnered programs across cancer, diabetes, and cardiovascular disease
Is LGND a Good Stock to Buy?
UQS Score rates LGND as Good overall, reflecting a balanced profile with meaningful strengths and a few areas worth monitoring.
Ligand's Growth and Risk pillar ratings stand out as relative positives. The royalty-driven business model provides revenue diversification across many partners and therapeutic areas, which tends to reduce single-asset concentration risk. The pipeline of partnered clinical programs adds optionality without requiring proportional capital deployment.
The Valuation pillar is rated Elevated, suggesting the market may already be pricing in a favorable outlook — leaving less room for error if partner programs disappoint. Quality and Moat pillar ratings are Neutral, indicating the business has not yet demonstrated a wide structural advantage relative to sector peers.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LGND pay dividends?
No — Ligand Pharmaceuticals Incorporated does not currently pay a dividend.
Ligand does not currently pay a dividend. For a royalty-focused biopharmaceutical company, this is consistent with a strategy of reinvesting capital into new licensing deals, royalty acquisitions, and portfolio expansion. Investors seeking income may look elsewhere, while those focused on capital appreciation may find the reinvestment approach aligned with long-term growth objectives.
When does LGND report earnings?
Ligand Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results for Ligand tend to reflect royalty payment timing and milestone receipts from partners, which can create variability from one period to the next. The underlying trajectory of the royalty portfolio is generally more informative than any single quarter's headline figures.
For the most recent quarter's results and guidance, visit Ligand Pharmaceuticals' investor relations page directly.
LGND Price History
+208.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Ligand Pharmaceuticals Incorporated?
Based on Ligand Pharmaceuticals Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LGND Long-term Outlook
Ligand's Good Growth pillar rating points to a business with expanding royalty streams as partner drugs gain broader adoption. The Good Risk rating suggests the diversified, asset-light model provides a degree of resilience. However, the Elevated Valuation pillar is a meaningful consideration — the current price appears to reflect optimistic assumptions, which raises the bar for execution across the partner portfolio.
Growth drivers
- Expansion of royalty receipts as partnered medicines grow market share globally
- New licensing deals and royalty acquisitions that broaden the portfolio
- Captisol platform adoption by additional pharmaceutical partners
Key risks
- Elevated valuation leaves limited margin of safety if partner programs underperform
- Revenue concentration in a small number of high-value royalty streams
- Clinical or regulatory setbacks at partner companies that reduce milestone and royalty income
LGND vs Peers
Ligand operates in a niche corner of biopharma — royalty and licensing — but competes for investor attention alongside other specialty biopharmaceutical companies.
Amicus focuses on rare metabolic diseases with its own commercial products, contrasting with Ligand's partner-dependent royalty model.
Xenon is a clinical-stage company concentrated on ion channel biology for neurological conditions, carrying a higher binary development risk than Ligand's diversified royalty approach.
Terns is an early-stage biopharma targeting metabolic diseases, representing a more concentrated pipeline bet compared to Ligand's broad royalty portfolio.
Frequently Asked Questions
What does Ligand Pharmaceuticals do?
Ligand Pharmaceuticals is a biopharmaceutical company that licenses its technologies — most notably its Captisol drug-formulation platform — to pharmaceutical partners. It earns royalties and milestone payments as those partners develop and commercialize medicines across oncology, infectious disease, osteoporosis, and other therapeutic areas.
Does LGND pay dividends?
Ligand does not pay a dividend. The company reinvests capital into acquiring new royalty interests and expanding its licensing portfolio rather than returning cash to shareholders through regular distributions.
When does LGND report earnings?
Ligand reports on a standard quarterly cadence. Because royalty receipts and milestone payments can vary by quarter, the full-year trajectory is often more meaningful than any individual report. Check Ligand's investor relations page for the current schedule.
Is LGND a good stock to buy?
UQS Score rates LGND as Good overall. The Growth and Risk pillars are relative strengths, while the Valuation pillar is rated Elevated. Whether that profile fits your portfolio depends on your own risk tolerance and investment horizon. The full pillar breakdown is available to UQS Pro members.
Is LGND overvalued?
The UQS Valuation pillar for LGND is rated Elevated, which indicates the current market price appears to reflect optimistic assumptions relative to fundamentals. This does not mean the stock will decline, but it does suggest a higher bar for the business to meet investor expectations.
How does LGND compare to its competitors?
Unlike Amicus Therapeutics, Xenon Pharmaceuticals, or Terns Pharmaceuticals — which carry more direct clinical development risk — Ligand's royalty and licensing model spreads risk across many partners and programs. This asset-light structure differentiates Ligand within the specialty biopharma space.
What is LGND's market cap bracket?
Ligand Pharmaceuticals is classified as a mid-cap company. This places it in a range that typically offers more liquidity than small-cap peers while still carrying meaningful growth potential relative to large-cap pharmaceutical companies.
Who founded Ligand Pharmaceuticals?
Ligand Pharmaceuticals was founded in 1992. Detailed founding history, including the names of original founders, is widely available through the company's official history and public filings.
Is LGND a long-term quality investment?
As a long-term quality indicator, LGND's Good UQS Score reflects a business with diversified royalty streams and manageable risk — but the Elevated Valuation and Neutral Quality and Moat ratings suggest the long-term case depends heavily on continued portfolio expansion and partner execution. Pro members can view the complete pillar analysis.
What is the main competitive advantage of Ligand Pharmaceuticals?
Ligand's primary competitive advantage is its Captisol drug-formulation technology, which improves the solubility and stability of drug compounds and has been adopted by numerous pharmaceutical partners. Combined with its diversified royalty portfolio, this creates recurring revenue without the capital intensity of traditional drug development.
What sector does LGND belong to?
Ligand Pharmaceuticals operates in the Healthcare sector, specifically within specialty biopharmaceuticals. Its royalty and licensing focus makes it somewhat distinct from traditional drug developers, as it earns income from partner commercialization rather than direct sales.
Is LGND a growth stock or value stock?
Based on UQS pillar ratings, LGND leans toward the growth side — the Growth pillar is rated Good, reflecting expanding royalty streams. However, the Elevated Valuation rating means it does not screen as a traditional value opportunity. It may appeal most to investors comfortable paying a premium for a differentiated business model.
Unlock Full LGND Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare LGND side-by-side with sector peers
- ✓Track royalty portfolio growth and risk indicators
- ✓Get the complete analyst-grade quality breakdown
- ✓Screen mid-cap healthcare stocks by pillar strength
Pro Analysis
LGND — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 57.4 | 46.6 | 41.0 | 89.7 | 77.7 | 39.5 | -0.3 |
| May 5, 2026 | 57.7 | 46.6 | 41.0 | 89.7 | 77.7 | 41.1 | +0.3 |
| May 3, 2026 | 57.4 | 46.6 | 41.0 | 88.6 | 77.7 | 41.1 | 0.0 |
| May 1, 2026 | 57.4 | 46.6 | 41.0 | 88.6 | 77.7 | 40.9 | +2.4 |
| Apr 26, 2026 | 55.0 | 46.6 | 41.0 | 77.5 | 77.7 | 39.7 | +0.2 |
| Apr 19, 2026 | 54.8 | 46.6 | 41.0 | 77.6 | 77.7 | 38.2 | -1.0 |
| Apr 18, 2026 | 55.8 | 46.9 | 41.0 | 77.6 | 77.7 | 44.0 | -0.7 |
| Apr 17, 2026 | 56.5 | 46.9 | 41.0 | 77.6 | 77.7 | 48.8 | +0.4 |
| Apr 16, 2026 | 56.1 | 46.6 | 41.0 | 77.4 | 77.7 | 47.2 | -0.4 |
| Apr 15, 2026 | 56.5 | 46.8 | 41.0 | 77.4 | 77.7 | 49.1 | -2.2 |
LGND — Pillar Breakdown
Quality
— 60.5/100 (25%)Ligand Pharmaceuticals Incorporated shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 90.1/100 (20%)Ligand Pharmaceuticals Incorporated is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 78.3/100 (15%)Ligand Pharmaceuticals Incorporated carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 40.8/100 (15%)Ligand Pharmaceuticals Incorporated has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)Ligand Pharmaceuticals Incorporated possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LGND.
Score Composition
Financial Data
More Stock Analysis
How is the LGND UQS Score Calculated?
The UQS (Unified Quality Score) for Ligand Pharmaceuticals Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ligand Pharmaceuticals Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ligand Pharmaceuticals Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.